Stelara

Adult patients ≥18 yr w/ moderate to severe plaque psoriasis who failed to respond to, or who have a CI to, or are intolerant to other systemic therapies including cyclosporin, MTX or PUVA. Monotherapy or in combination w/ MTX for adult patients ≥18 yr w/ active psoriatic arthritis when response to previous non-biological DMARD therapy has been inadequate; inhibiting structural damage progression. Adults w/ moderately to severely active Crohn's disease who have failed or were intolerant to immunomodulators or corticosteroids but never failed treatment w/ TNF blocker; failed or were intolerant to treatment w/ ≥1 TNF blockers. Adult patients w/ moderately to severely active ulcerative colitis who have had inadequate response w/, lost response to, or were intolerant to either conventional therapy or biologic or have medical CI to such therapies. Ped patients (childn & adolescents ≥6 yr) w/ moderate to severe plaque psoriasis who are inadequately controlled by, or are intolerant to other systemic therapies or phototherapies.

SC Plaque psoriasis Adult weighing >100 kg 90 mg initially & 4 wk later followed by dosing every 12 wk, ≤100 kg 45 mg initially & 4 wk later followed by dosing every 12 wk. Re-treatment w/ dosing regimen of wk 0 & 4 after therapy interruption has been shown to be safe & effective. Ped ≥6 yr weighing >100 kg 90 mg at wk 0 & 4 then every 12 wk thereafter, ≥60 to ≤100 kg 45 mg at wk 0 & 4 then every 12 wk thereafter, <60 kg 0.75 mg/kg at wk 0 & 4 then every 12 wk thereafter. Psoriatic arthritis 45 mg at wk 0 & 4 then every 12 wk thereafter. Patient weighing >100 kg 90 mg may be used alternatively. IV infusion Crohn's disease & ulcerative colitis A single IV tiered dose based on body wt, followed by 90 mg SC dosing 8 wk later, then every 8 wk thereafter. Patient weighing >85 kg 520 mg, >55 kg to ≤85 kg 390 mg, ≤55 kg 260 mg.

Hypersensitivity.

Immunosuppressants

L04AC05 - ustekinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

POM